afm13
mAbexperimentalMulti-specific
Clinical trial activity
7 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2010 (NCT01221571)
Timeline
Indications
Mechanism of action
TNFRSF8 inhibitor
- Low affinity immunoglobulin gamma Fc region receptor III-AImmunity, passive
FCGR3A immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Also known as
- afm13
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05883449 | Phase 2 | Oct 10, 2023 | Affimed GmbH, Artiva Biotherapeutics, Inc. |
| NCT04101331 | Phase 2 | Dec 31, 2019 | Affimed GmbH, Columbia University |
| NCT04074746 | Phase 1 | Oct 1, 2019 | University of Texas at Houston |
| NCT03192202 | Phase 1/Phase 2 (Phase 2) | Jul 17, 2017 | Columbia University |
| NCT02665650 | Phase 1 | May 1, 2016 | Affimed GmbH, Merck, The Leukemia and Lymphoma Society |
| NCT02321592 | Phase 2 | May 1, 2015 | Affimed GmbH, The Leukemia and Lymphoma Society, University of Cologne |
| NCT01221571 | Phase 1 | Oct 1, 2010 | Affimed GmbH, University of Cologne, University of Texas at Houston |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Affimed GmbH | For profit | 5 | 4 | 2 | 2010 |
| Columbia University | Academic/Hospital | 2 | 1 | 1 | 2017 |
| The Leukemia and Lymphoma Society | Academic/Hospital | 2 | 0 | 2 | 2015 |
| University of Cologne | Academic/Hospital | 2 | 1 | 2 | 2010 |
| University of Texas at Houston | Academic/Hospital | 2 | 1 | 1 | 2010 |
| Artiva Biotherapeutics, Inc. | For profit | 1 | 0 | 1 | 2023 |
| Merck | For profit | 1 | 0 | 1 | 2016 |
7 organizations
Page 1 / 1